A Phase 1/2 Study of INCB099280 in Combination With Axitinib in Adults With Advanced Solid Tumors

• Research type

  Research Study

• Full title

  A Phase 1/2 Study of INCB099280 in Combination With Axitinib in Adults With Advanced Solid Tumors

• IRAS ID

  1008251

• Contact name

  Carol Penning

• Contact email

  cpenning@incyte.com

• Sponsor organisation

  Incyte Corporation

• Eudract number

  2022-003663-13

• Research summary

  The study is looking at whether axitinib can be safely given with INCB099280 (an agent that helps the immune system identify and fight cancer cells ) and if this may result in better clinical outcomes in adults with previously treated advanced clear-cell or rare histological subtype epithelial gynecological cancers who are not able to have curative surgery or (chemo)radiation.

• REC name

  London - City & East Research Ethics Committee

• REC reference

  23/LO/0762

• Date of REC Opinion

  13 Oct 2023

• REC opinion

  Further Information Favourable Opinion